D&d Pharmatech Inc.

Plus: eGenesis names Jay Barth CMO and updates from Cytodyn, Sera, Context, Kelso

With U.S. institutions under strain, Europe must act decisively to support innovation and secure a bigger role in biotech’s future

Plus: Deerfield raises $600M for next vehicle, Vivo’s refreshed evergreen fund, and more

Plus: Updates from Enara, Paq, Priothera, Eccogene

Targeted protein degraders and selective small molecules face off against SMARCA4-mutant cancers at AACR

Special guests join BioCentury to discuss how industry can navigate the new complexity. Plus: the Belgian biotech ecosystem

BioCentury’s roundup of translational innovations also includes microglia replacement for neurological disorders and enhanced mRNA vaccine efficacy 

Compounded GLP-1s impact 1Q25 sales growth

How the corporate VC is evolving its portfolio strategy

At least 13 companies described preclinical KRAS degraders at the meeting